Brief: Metacrine, Inc. Reports Positive Results From Phase 1 Trial Of Met642
17/12/2020 11:33
Dec 17 (Reuters) - Metacrine, Inc. MTCR.O :
* METACRINE, INC. - REPORTS POSITIVE RESULTS FROM PHASE 1
TRIAL OF
MET642
* METACRINE, INC. - DOSES SELECTED FOR PHASE 2A TRIAL IN
PATIENTS
WITH NASH; ON-TRACK TO INITIATE IN 1H21 FOR MET642 TRIAL
* METACRINE, INC. - TREATMENT WITH MET642 IN TRIAL WAS SAFE
AND
GENERALLY WELL-TOLERATED AND DEMONSTRATED A SUSTAINED
PHARMACOKINETIC PROFILE
Source text for Eikon: ID:nGNX8vwhqj
Further company coverage: MTCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Metacrine
See all newsMetacrine Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Metacrine - Filed Certificate Of Dissolution With Secretary Of State Of State Of Delaware To Effect Complete Liquidation And Dissolution Of Company
Brief: Metacrine Inc Common Stock Will Be Delisted From Nasdaq
Brief: Metacrine Inc- On Jan 31, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Metacrine CEO Preston Klassen Was Terminated From All Positions